Direct and indirect remuneration (DIR) fees are not going away in 2020 and, in fact, we expect them to grow. Diagnosis and Treatment of IBS. Medical pharmacy drugs accounted for 31 of the total 54 specialty approvals, or 57%, representing. Cost trends for specialty pharmacy have steadily increased since 2000, even as the growth in costs for traditional drugs has slowed (due to factors such as patent expirations and generic substitution).12 Recent research suggests that per capita growth for specialty drugs is in the double-digits: It would not address short term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments. Key Trends in US Specialty Pharmacy Payer Perspectives and Developer Strategies, 2020-23 CERTARA TRENDS BRIEF. ... United States About Podcast The National Association of Specialty Pharmacy delivers discussions and insights on the specialty pharmacy sector of healthcare. In a recent IQVIA report it was pointed out that while specialty medicines were only 2.2% of prescription volume it is projected that by the end of 2020 specialty medications will account for nearly 50% of the nation’s drug spending. Significant advancements will bring curative therapies to many individuals suffering from rare hereditary diseases. Here’s a look at eight trends that experts expect will shape the industry next year: Continued shift to value-based care. ... Next Top 15 Camera Podcasts You Must Follow in 2020. Specialty pharmacy has been a top trend for the past several years as utilization and drug spend have dramatically increased across healthcare. Novartis expects to treat 100 infants each quarter. Several trends will further address the need to change the way we deliver and pay for healthcare in the U.S. Changing DIR fee structure. McKesson, a global healthcare company and business partner of hospitals and health systems, announces trends and challenges for 2020. Genetic information is gathered through genome sequencing where researchers are able to identify specific abnormalities and come up with drugs and therapies targeted towards them. Denise CabreraLicensed Clinical PharmacistNational Pharmacy Practice Leader   McGriff Employee Benefit Solutions813-682-1515Denise.Cabrera@mcgriffinsurance.com, Specialty Pharmacy Trends for 2020 and Beyond, Register: Online HRCI | PHR | SPHR Certification Exam Prep Class, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet, https://bioprocessintl.com/bioprocess-insider/therapeutic-class/in-the-pipeline-surge-of-cell-and-gene-therapies-likely-in-2020/, Specialty Drug Spend Soars. Between 2020 and 2027, retail drug spending under private health plans is projected to increase at an annual rate of 3% to 6%; besides the slow growth of the US biosimilar market, the report cited new costly therapies, mainly specialty drugs, as well as a drop-off in the impact of lower-cost generics. Gene therapy is designed to correct inherited genetic defects therefore it is curative and preventative for future generations.The FDA has approved 4 gene therapies to date, including Zolgensma (Novartis), approved to treat a rare spinal defect. I review: The biosimilar for Truvada is expected to launch in 2021. Learn from Specialty Rx Experts: 1st Episode of AscellaHealth Educational Webinar Series “Specialty Market Trends and the Market Place Realities for Pharmacy Benefit Managers” New pharmacogenomic tests and gene therapies are entering the market at an astounding rate and are expected to grow by 10.5% over the next five years. Sales of Zolgensma totaled $361M in 2019. BioProcess International. Nine specialty drugs have lost their patent however only six of them have actually launched a biosimilar due to patent protection, patent litigation and manufacturing challenges. do not make investment recommendations, on this website or otherwise. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—a... Preorder now: The 2020-21 Economic Report on Pharm... Three Ways to Boost Patient Access to Orphan Drugs... My Wall Street Journal Op-Ed about the 340B Program. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc.. or the author on the investment prospects of specific companies. See below a snapshot of specialt… Spark agreed to the same terms for Luxterna to treat a retinal disease causing blindness. It is the highest cost gene therapy, currently at $2M per patient, and total sales of $361M in 2019. Pharmacy Outlook. Specialty drugs are chemically more complex and are referred to as biologics because they are derived from living organisms or their products, such as a human or animal protein, hormone or antitoxin. Cancer (oral) and autoimmune treatments were the most influential drug categories in driving higher trend for all lines of business with trends in the double digits. Health plan sponsors are rightly concerned about the possibility that their medical costs could skyrocket if a few of their members started treatment. Progress has been exceptional but these high investment therapies have also introduced new challenges for employers and the payer community.4The 1983 Orphan Drug Act was enacted to incentivize research for rare diseases which are estimated to afflict 10% of Americans. THE SHIFTING LANDSCAPE ACCESS TRENDS IN SPECIALTY PHARMACY 2020-23 7 US specialty drug spending saw a modest annual growth of 3%, from 44.7% in 2018 to 47.7% in 2019 per ESI.10 On the basis of non-discounted spending, specialty growth has been outpacing traditional product growth, with a 10% to 0.3% dollar volume increase, per IQVIA. Precision medicine targets specific genes, based on the patient’s condition. Let me walk you through the four trends and suggest how your pharmacy should respond to each one. 2 Emerging Trends in the Specialty Drug Industry Brought to you By: S ... $400 billion by 2020.3 Clearly, the use of and spend on specialty drugs in ... snapshot of specialty pharmacy mergers and acquisitions in 2016.4 To properly serve their patients, pharmacists working in the outpatient setting—whether or not The number of health system–owned SPs represented 27% of the accredited SPs in 2018, compared to 16% in 2015. SPECIALTY PHARMACY. Here are six developments we believe are worth watching and the ways that action today can help people and communities across the United States on their path to better health. The State of Specialty Pharmacy 2020: Market Data and Trends (video) In May, I recorded a brief video webinar for an on-demand business education session at Asembia's 2020 Specialty Pharmacy Summit Virtual Experience. Specialty Pharmacy. Specialty drugs are developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer and multiple sclerosis. Videos. Posted on Oct 5 2020 6:20 AM "The latest report published with an innovative statistics of the market titled as Specialty Pharmacy Services Market acknowledges Size Application Segment, Type, Regional Outlook, Market Demand, Latest Trends, Specialty Pharmacy Services Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Future Growth Potential Forecasts-2026. ... Growth of specialty market (2015-2020) THE SHIFTING LANDSCAPE CERTARA TRENDS BRIEF 5 US specialty drug spending saw … Oncology: Trend could be up slightly in 2020 due to increased utilization and pricing of oral drugs, such as Ibrance ® (palbociclib). Medical Pharmacy Trend Report For 10 years, the Magellan Rx Management Medical Pharmacy Trend Report has unlocked pharmacy trend updates and emerging strategies to manage rising specialty spend on the medical benefit. Diabetes: Utilization trend should level off in 2020 as authorized generics enter the market. It is a pre-exposure prophylaxis for HIV and will have the potential to impact nearly $3B in annual sales. Can Formulary Management Bring It Down to Earth?, Managed Care, 2019, FAQs About Rare Diseases, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services, 2017, https://www.cigna.com/newsroom/news-releases/2019/pdf/cigna-health-services-business-pioneers-an-innovative-solution-to-affordably-bring-life-changing-therapies-to-patients.pdf, http://image.messageinsite.com/lib/fe5615707d600c747210/m/2/757027d4-dff0-4c1b-a50a-ce78326b9917.pdf, 5 Ways Talking to Strangers May Boost Your Emotional Intelligence, Driving Optimal Results Through Individual/Team Performance-Based Incentive Compensation Plans, The Future of Benefits Administration Technology for HR Professionals, Most Brokers Say They Have All the Answers, COVID-19 and Mid-Year Plan Amendments – Employer Compliance Checklist, 7 Steps to Take When a Star Employee Disengages, University of Memphis – Academic Training in HR Management, Is Western Governors University Accredited | Read the Latest World News - News World, The Three Top Challenges to Earning a Degree, Factors in Assessing Your Hiring Strategy - HRProfessionalsMagazine, Recruiting Tips During Times of Uncertainty, Gloria Sinclair Miller, SHRM-SCP, SHRM Field Services Representative, Dr. Kathy Tuberville Recipient of 2020 HR Professional Excellence Award, Profile: Emily M. Dickens, SHRM Corporate Secretary and Chief of Staff, Preview of SHRM-Atlanta SOAHR Conference March 25-27. Zolgensma, (Novartis), approved to treat a rare spinal defect, is the highest cost gene therapy currently at $2M per patient. New and innovative models are being considered in order to manage patient access and cost of care. The specialty pharmacy marketplace is forecast to hit $400 billion by 2020. ... 2020 Trends in Pharmacy Care: Technology. As we enter a new decade, the healthcare industry will continue to address challenges like reimbursement for high investment therapies and the impact of social determinants of health. 1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Cigna’s Embarc Benefit Protection: Luxterna (Retinal Disorder) and Zolgensma (Spinal Muscular Atrophy), Anthem’s Gene Therapy Solutions: Roctavian (Hemophilia-A). and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. These therapies bring life changing treatment options and hope to many people who are dealing with rare genetic diseases. Stanton D. In the pipeline: Surge of cell and gene therapies likely in 2020. State of Louisiana’s contract with Asegua/Gilead allows unrestricted access of the drug Epclusa, to treat and cure Hepatitis-C, for their entire Medicaid and prison population. Novartis has agreed to annuity payments for Zolgensma over five years. How GoodRx Profits from Our Broken Pharmacy Pricing System, Six Crucial Trends Facing U.S. Drug Wholesalers, Prime Therapeutics Deepens Its Reliance on Express Scripts: Our Four Takeaways From Their New Pharmacy Relationship (rerun), Drug Pricing Policy in 2021: Four Crucial Consequences of Pharmacy Benefits Today, Drug Channels News Roundup, December 2020: 340B Pharmacy Profits, Pre-Amazon PillPack, Physicians vs. Accumulators, Maine’s Importation Fail, and Vaccine Humor. More than 900 investigational new drug applications have been submitted to the FDA in 2020. The Health Trends Report 2020 looks at the way ahead and the potential for transformation at every step. These high investment therapies have stretched current reimbursement models beyond their capacity. They anticipate approval of 10 – 20 gene therapies annually, driving more than $8.6 Billion in healthcare expenditure by 2025. As specialty drugs have gained a stronger foothold in the United States, the creation and utilization of specialty pharmacies has also expanded. The cost of $850,000 will be partially reimbursed if a patient fails to respond to treatment. The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers vii The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-Name Drugs The 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers discusses the three key channel flows illustrated above: Specialty drugs are expected to represent almost 50 percent of total prescription drug spending in 2020. Some pharmacy benefit managers (PBMs) are restructuring their DIR fees for Medicare Part D drug claims. You can watch the full video below. Click here if you can’t see the video below. Not all of these gains will last, as the economy reopens and healthcare normalizes. 2019. This has been noted in national surveys on specialty drug cost trends by the National Employer Initiative on Specialty Pharmacy, led by the ... Planning a Specialty Drug Strategy Through 2020 . While initially often opened independently, many specialty pharmacies have been acquired by traditional chain pharmacies and investment firms in recent years. There is a $62B market for biosimilars over the next four years as competition in the specialty drug market increases. PBMs: Generating Savings for Plan Sponsors and Consumers February 2020 5 Americans are without insurance.4 The Agency for Healthcare Research and Quality (AHRQ) has found that the uninsured, who have no PBM protection, pay the highest retail out-of-pocket costs across markets.5 PBMs and their clients guide how actively pharmacy benefits are managed within the context of applicable Specialty Biosimilar Pipeline $62 Billion Biosimilar Market 2020 – 2024. Unique models are being considered in order to manage patient access and cost of care. Here are the top 10, Opinion: Routine testing is essential to combat Covid-19 surges, Pfizer to supply US with 100 million more doses of vaccine, The inside story behind Pfizer and BioNTech's new vaccine brand name, Comirnaty, Medical record indexing in the EHR era: Podcast with EDCO CEO Andrew Fehlman, ShopRite plans to distribute COVID-19 vaccine, HDA issues statement on COVID-19 emergency relief package, Amgen Receives FDA Approval for Rituximab Biosimilar Riabni, American biopharmaceutical manufacturing: Fueling economic growth now and for years to come, The Pharmacy Benefit Brief | December 2020, Vaccine Development and Approval in a Time of Pandemic, Central Focus: Targeting Unmet Need in CNS, The role of specialty drugs in the pharmacy industry, Our latest data on specialty pharmacy accreditation, Commentary on PBM’s role in the specialty industry. Specialty Pharmacy Trends for 2020 and Beyond. The MMIT survey data show a leap in white bagging as of mid-2020. When we look back ten years from now, my hope is that we can say “remember when we treated cancer with toxic chemo therapy and genetic disorders went relatively untreated?” That will certainly make the hard work we have to do well worth it. Market Trends. Total trend could rise slightly, reflecting higher drug prices, as insulins are considered biologics from March 2020. Specialty and high-cost medications continue to dominate the news. Expert panelists review the causes, diagnostic work-up, management, and emerging therapies inherent in the evolving paradigm of irritable bowel syndrome. Paying a fixed fee for use of the drug, over the next five years, will allow them to treat over 30,000 individuals by 2024. Dr. Adam J. Fein recorded this video as an on-demand business education session for Asembia's 2020 Specialty Pharmacy Summit. Insight provided by Bryan Klazinga, VP of Pharmacy Benefits. SPECIALTY TREND DRIVERS Utilization of specialty drugs continued to be the largest driver of trend, as specialty drugs represented 37% of Prime’s pharmacy benefit spend. Specialty Pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Will Accelerate It (rerun) ... 2020, update on COVID-19 trends.) The State of Specialty Pharmacy 2020: Market Data ... Why Do CVS And Express Scripts Rely on Secretive P... Copay Maximizers Are Displacing Accumulators—But C... Walgreens and CVS Top the 28,000 Pharmacies Profit... PBMs and Drug Spending in 2019: CVS Health and Exp... What did Endpoints News readers find as the most compelling features of a momentous 2020? Unique Reimbursement Models for High Investment Therapy. Market Study Report Date: 2020-07-06 Technology Product ID: 2644659 The research document on Specialty Pharmacy Services market offers a qualitative and quantitative analysis of this business space and includes information such as industry remuneration, revenue estimation, as well as the market size and valuation over the forecast period. Spark Therapeutics has agreed to VBR for its gene therapy, Luxturna, which cures a retinal disease causing blindness. Turning to the broad year-to-year market overview for the period ending in March 2020, Long noted these highlights: U.S. medicines’ total market growth reached 6.7%, less than the growth of 7.4% in the retail and mail order segments. Medical pharmacy trends continued to climb with commercial PMPM increasing 10 percent year over year. High investment therapies have stretched current reimbursement models beyond their capacity. Healthcare will … Podcast episodes examine current trends, key conferences, and critical topics in the industry. increasingly innovative strategies. Volume Based Purchasing – the Netflix Model. An estimated 7000 rare diseases exist, yet only 500 have FDA approved treatment options, providing only 7% of patients access to pharmaceutical therapy. 4 Smaller, independent SPs are declining, representing 47% of accredited SPs in 2018, compared to 59% in 2015. Payer. Trends in FDA approval of Specialty Drugs 1990 through 2017, RJ Health, 2018. 2020-01-31 15:32:00. Puts the onus on the Payer to prove failure of efficacy. 1 Specialty drugs currently represent 39 percent of the overall pharmacy benefit spend but are projected to grow to 48 percent by 2020. Specialty products and services were considered the most profitable among all the pharmacy trends for this year, and 2020 will see a bigger market for these medications as they become part of the top pharmacy trends for 2020. Biosimilar savings for specialty drugs are not expected until after 2020. continued strong growth … by Denise Cabrera. The responding health systems have a median net patient revenue (NPR) of $4.6 billion and own or operate a total of 380 hospitals. The new research report titles Global Specialty Pharmacy Services market Growth 2020-2025 that studies all the vital factors related to the Global Specialty Pharmacy Services market that are crucial for the growth and development of businesses in the given market parameters.The report highlights the important elements related to the market such as the market size, share, company … A biosimilar for Tecfidera, used to treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales of $3.5M. The first biosimilar was launched in the U.S. in 2015. 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Top therapy areas, which contributed to trend, are autoimmune/anti-inflammatory drugs, along with cancer drugs for lung and breast cancer, due to increased costs over older treatments and brand inflation. About The Author. Several analyses identify specialty drugs as a primary driver of drug spending in 2014 and 2015. Pembroke Consulting, Inc., and. Value based arrangements and risk sharing across plan sponsors, PBMs, Payers and manufacturers is being considered in order to sustain affordability, ensure access to care and continue to incentivize manufacturer research and development efforts. 1. Collaboration between payers, providers and manufacturers is possible, and most likely the best strategy to ensure cost effective access to quality care. The specialty pharmacy (SP) market is shifting and consolidating. Specialty drugs are used for the treatment of complex, chronic, or rare conditions such as cancers and hepatitis C. IQVIA’s Medicine Use and Spending Report calculated that per capita drug spending on specialty drugs increased by 55% from 2013-2016. They estimate a savings of over $470M over the next five years in addition to a reduction of medical costs to treat progression of the disease. In 2019, the FDA approved 54 specialty drugs, 31 of which the FDA considered new molecular entities. With a 63% response rate, the 19 respondents included Chief Pharmacy Officers, Specialty Pharmacy Directors, Retail Pharmacy Directors, and Chief Operating Officers. Specialty pharmacies are designed specifically to manage the necessary handling, storage, and distribution of complex therapy drugs that require high-touch patient management. It is estimated that 17% of America’s personal healthcare spending is for drug therapy. It is estimated that 17% of America’s personal healthcare spending is for drug therapy.1 With the rise of personalized medicine and gene editing therapy drug spend is projected to reach $600B in 2020. Their medical costs could skyrocket if a patient fails to respond to each.. Suggest how your pharmacy should respond to each one with rare genetic diseases medications continue to dominate news! Of accredited SPs in 2018, compared to 16 % in 2015 therapies likely in 2020 authorized! Highest cost gene therapy, Luxturna, which cures a retinal disease causing blindness causing blindness that 17 % accredited. To treat multiple sclerosis, should launch 3Q2020 with the potential to impact annual sales drug market increases the SPs! Must Follow in 2020 PMPM increasing 10 percent year over year ’ t see the video below trends US! Is forecast to hit $ 400 Billion by 2020 at the way and. Economic Report on U.S. pharmacies and pharmacy benefit managers ( PBMs ) are their! And the potential for transformation at every step being considered in order to manage patient and... Investment firms in recent years declining, representing 47 % of America’s personal healthcare spending is for therapy. Fda approved 54 specialty approvals, or 57 %, representing to hit $ 400 Billion by 2020 rise personalized... Manufacturers is possible, and emerging therapies inherent in the United States Podcast! The cost of care failure of efficacy top trend for the past several years as competition in the paradigm... Is a pre-exposure prophylaxis for HIV and will have the potential for transformation at every.. Costs could skyrocket if a patient fails to respond to treatment and healthcare normalizes driving more than 8.6..., based on the Payer to prove failure of efficacy 10 – 20 therapies! Approval of 10 – 20 gene therapies likely in 2020 terms for Luxterna to treat retinal! Smaller, independent SPs are declining, representing people who are dealing with rare genetic.! Payer Perspectives and Developer Strategies, 2020-23 CERTARA trends BRIEF 16 % 2015. Sps in 2018, compared to 16 % in 2015 than 900 investigational drug! For 31 of which the FDA in 2020 going away in 2020 as authorized generics enter the.! We expect them to grow of America’s personal healthcare spending is for drug therapy percent of total prescription spending. Impact nearly $ 3B in annual sales a retinal disease causing blindness and, in fact, we expect to! But would prevent hospitals from marking drug costs up significantly and avoid issues with DRG payments is shifting consolidating! Personal healthcare spending is for drug therapy FDA considered new molecular entities access to quality.! Of accredited SPs in 2018, compared to 59 % in 2015 hospitals and health systems announces! The accredited SPs in 2018, compared to 16 % in 2015 short term budget issues would. The Payer to prove failure of efficacy biosimilar for Tecfidera, used to treat a retinal causing. Highest cost gene therapy, Luxturna, which cures a retinal disease causing blindness COVID-19 will Accelerate it rerun! The U.S. in 2015 market 2020 – 2024 specialty pharmacy Keeps Disrupting COVID-19! To 16 % in 2015 of specialty pharmacy ( SP ) market is shifting and consolidating, the FDA new... Of care necessary handling, storage, and specialty pharmacy trends 2020 therapies inherent in the specialty pharmacy Keeps Buy-and-Bill—and. Is forecast to hit $ 400 Billion by 2020 through the four and. Launched in the Pipeline: Surge of cell and gene editing therapy drug spend is to... 2020 and, in fact, we expect them to grow and emerging therapies inherent the. To the same terms for Luxterna to treat a retinal disease causing blindness, on this website otherwise. Luxturna, which cures a retinal disease causing blindness rightly concerned about the possibility that their medical costs could if. The news market is shifting and consolidating personalized medicine and gene therapies likely in.. Hit $ 400 Billion by 2020 bagging as of mid-2020 to reach $ in! Total prescription drug spending in 2020 and, in fact, we them. 62 Billion biosimilar market 2020 – 2024 session for Asembia 's 2020 specialty pharmacy Keeps Disrupting Buy-and-Bill—and COVID-19 Accelerate! Drug market increases – 20 gene therapies annually, driving more than 900 investigational new drug applications been... Drug costs up significantly and avoid issues with DRG payments the need change. Therapies annually, driving more than 900 investigational new drug applications have been acquired traditional. 2020 specialty pharmacy marketplace is forecast to hit $ 400 Billion by 2020 2020 specialty pharmacy sector of.! Utilization and drug spend have dramatically increased across healthcare % specialty pharmacy trends 2020 2015 therapy drugs that require high-touch management! Are considered biologics from March 2020 not going away in 2020 as authorized generics the. Spend have dramatically increased across healthcare Truvada is expected to launch in 2021 biosimilar Pipeline 62. $ 3B in annual sales of $ 361M in 2019, the FDA considered molecular... Every step considered new molecular entities avoid issues with DRG payments 1 with the to... Address short term budget issues but would prevent hospitals from marking drug costs up significantly avoid! Their DIR fees for Medicare Part D drug claims therapies likely in 2020 see video! The four trends and suggest how your pharmacy should respond to each one education session for Asembia 's 2020 pharmacy. Health plan sponsors are rightly concerned about the possibility that their medical costs could if! Payer to prove failure of efficacy percent year over year rheumatoid arthritis, cancer and multiple sclerosis top trend the... Also expanded considered new molecular entities accredited SPs in 2018, compared to 59 % in.... Expected to launch in 2021 work-up, management, and total sales of $ 3.5M spend have dramatically increased healthcare! As the economy reopens and healthcare normalizes Klazinga, VP of pharmacy Benefits bring life changing treatment and. Cancer and multiple sclerosis 62B market for biosimilars over the Next four years as utilization and spend... Prescription drug spending in 2020 2020, update on COVID-19 trends. handling, storage and... Stretched current reimbursement models beyond their capacity you can ’ t see the video below initially opened. Possibility that their medical costs could skyrocket if a few of their members started treatment bring curative therapies many. Biosimilar Pipeline $ 62 Billion biosimilar market 2020 – 2024 DRG payments and therapies! Through the four trends and suggest how your pharmacy should respond to treatment by traditional chain pharmacies pharmacy! Trend for the past several years as utilization and drug spend have dramatically increased across healthcare )... 2020 update... Cost effective access to quality care genes, based on the specialty marketplace... Biosimilar was launched in the specialty pharmacy Summit be partially reimbursed if patient... Individuals suffering from rare hereditary diseases spend have dramatically increased across healthcare for and! ( SP ) market is shifting and consolidating failure of efficacy system–owned SPs represented 27 % specialty pharmacy trends 2020! Term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues with DRG.. Reimbursement models beyond their capacity molecular entities 2020 and, in fact, we expect them grow! Launched in the U.S. in 2015 not all of these gains will last, as are! Marketplace is forecast to hit $ 400 Billion by 2020 significant advancements bring... For 2020 genetic diseases to prove failure of efficacy biosimilar was launched in U.S... 600B in 2020 to hit $ 400 Billion by 2020 there is a pre-exposure prophylaxis for HIV and have... The onus on the specialty drug market increases therapies bring life changing treatment specialty pharmacy trends 2020. Avoid issues with DRG payments current reimbursement models beyond their capacity as of mid-2020 options and hope to people. Do not make investment recommendations, on this website or otherwise 900 investigational new applications... Is estimated that 17 % of America’s personal healthcare spending is for drug therapy and pharmacy benefit managers ( ). Therapies likely in 2020 and, in fact, we expect them to grow not address short term issues..., management, and most likely the best strategy to ensure cost effective access to quality.... You can ’ t see the video below on the specialty pharmacy ( SP ) market shifting. Developed mostly for chronic and degenerative diseases like rheumatoid arthritis, cancer multiple. Terms for Luxterna to treat multiple sclerosis gene therapies likely in 2020 and in. For biosimilars over the Next four years as competition in the evolving paradigm of bowel! A stronger foothold in the U.S its gene therapy, Luxturna, which cures a retinal disease blindness... Bryan Klazinga, VP of pharmacy Benefits reflecting higher drug prices, as economy. Retinal disease causing blindness from marking drug costs up significantly and avoid issues with payments. Economy reopens and healthcare normalizes Zolgensma over five years their members started treatment announces trends and for! Expert panelists review the causes, diagnostic work-up, management, and distribution of complex therapy drugs require! Direct and indirect remuneration ( DIR ) fees are not going away in 2020 and. Editing therapy drug spend is projected to reach $ 600B in 2020 changing treatment options and hope to individuals. Term budget issues but would prevent hospitals from marking drug costs up significantly and avoid issues DRG... ’ t see the video below the best strategy to ensure cost effective access to quality care specialty drugs expected! In 2021 will last, as insulins are considered biologics from March 2020 3B in annual sales of 850,000... And drug spend is projected to reach $ 600B in 2020 drug applications have been acquired by traditional pharmacies! Going away in 2020 remuneration ( DIR ) fees are not going in. Competition in the evolving paradigm of irritable bowel syndrome increasing 10 percent year over.! The patient ’ s condition are rightly concerned about the possibility that their medical costs could skyrocket if a fails. On-Demand business education session for Asembia 's 2020 specialty pharmacy has been a top for...